Therefore, we used an ADAM10 inhibitor (GI254023X, a competive inhibitor with 100-fold higher specificity for ADAM10 versus ADAM17 [36]) during infection to increase peripheral resistance and vessel stiffness simultaneously. This evidence concerns the gene ADAM17 and infection.